SK285905B6 - Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie - Google Patents
Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie Download PDFInfo
- Publication number
- SK285905B6 SK285905B6 SK1090-2000A SK10902000A SK285905B6 SK 285905 B6 SK285905 B6 SK 285905B6 SK 10902000 A SK10902000 A SK 10902000A SK 285905 B6 SK285905 B6 SK 285905B6
- Authority
- SK
- Slovakia
- Prior art keywords
- acid
- derivatives
- weight
- pheromone composition
- pheromone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 161
- 239000003016 pheromone Substances 0.000 title claims abstract description 121
- 230000028327 secretion Effects 0.000 title claims abstract description 22
- 210000004907 gland Anatomy 0.000 title abstract description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 114
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 63
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 57
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 55
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 55
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000005642 Oleic acid Substances 0.000 claims abstract description 55
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 55
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 55
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 55
- 241000124008 Mammalia Species 0.000 claims abstract description 48
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 40
- 229930195729 fatty acid Natural products 0.000 claims abstract description 40
- 239000000194 fatty acid Substances 0.000 claims abstract description 40
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 34
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims abstract description 31
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000021360 Myristic acid Nutrition 0.000 claims abstract description 25
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 22
- 150000001298 alcohols Chemical class 0.000 claims abstract description 17
- 230000036506 anxiety Effects 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 150000002576 ketones Chemical class 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 150000002170 ethers Chemical class 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 206010001488 Aggression Diseases 0.000 claims abstract description 6
- 230000004580 weight loss Effects 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 70
- 235000021313 oleic acid Nutrition 0.000 claims description 54
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 43
- 239000005639 Lauric acid Substances 0.000 claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 27
- 235000020778 linoleic acid Nutrition 0.000 claims description 27
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 27
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 26
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 22
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 210000005075 mammary gland Anatomy 0.000 claims description 13
- 230000016571 aggressive behavior Effects 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- 229920001451 polypropylene glycol Polymers 0.000 claims description 11
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 9
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 claims description 9
- 229940031439 squalene Drugs 0.000 claims description 9
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000002453 shampoo Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 229930182558 Sterol Natural products 0.000 claims description 5
- 208000012761 aggressive behavior Diseases 0.000 claims description 5
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 150000003432 sterols Chemical class 0.000 claims description 5
- 235000003702 sterols Nutrition 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 4
- 229960000735 docosanol Drugs 0.000 claims description 3
- 230000006400 anxiety behaviour Effects 0.000 claims description 2
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 claims description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 8
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 4
- 150000001735 carboxylic acids Chemical class 0.000 claims 4
- 125000003158 alcohol group Chemical group 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 40
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229960004488 linolenic acid Drugs 0.000 abstract 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 59
- 229940068196 placebo Drugs 0.000 description 59
- 241000282887 Suidae Species 0.000 description 47
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 42
- 208000027418 Wounds and injury Diseases 0.000 description 36
- 230000035882 stress Effects 0.000 description 33
- 101001017254 Homo sapiens Myb-binding protein 1A Proteins 0.000 description 30
- 101000582992 Homo sapiens Phospholipid phosphatase-related protein type 5 Proteins 0.000 description 30
- 102100034005 Myb-binding protein 1A Human genes 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 230000006378 damage Effects 0.000 description 26
- 208000014674 injury Diseases 0.000 description 26
- 238000011156 evaluation Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- -1 ACTH Chemical compound 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 208000021017 Weight Gain Diseases 0.000 description 16
- 235000019786 weight gain Nutrition 0.000 description 16
- 230000004584 weight gain Effects 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 230000006399 behavior Effects 0.000 description 13
- 235000021051 daily weight gain Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241000282898 Sus scrofa Species 0.000 description 12
- 230000007717 exclusion Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 102100039377 28 kDa heat- and acid-stable phosphoprotein Human genes 0.000 description 10
- 101710176122 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 210000005069 ears Anatomy 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 230000000474 nursing effect Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 description 8
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 241000283903 Ovis aries Species 0.000 description 7
- 244000309466 calf Species 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 6
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 5
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 5
- KZJWDPNRJALLNS-STIDJNKJSA-N gamma-sitosterol Natural products CC[C@@H](CC[C@@H](C)[C@@H]1CC[C@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C KZJWDPNRJALLNS-STIDJNKJSA-N 0.000 description 5
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 5
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 4
- SOFRHZUTPGJWAM-UHFFFAOYSA-N 3-hydroxy-4-[(2-methoxy-5-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound COc1ccc(cc1N=Nc1c(O)c(cc2ccccc12)C(=O)Nc1cccc(c1)[N+]([O-])=O)[N+]([O-])=O SOFRHZUTPGJWAM-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 101100438971 Caenorhabditis elegans mat-1 gene Proteins 0.000 description 4
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 4
- HJZLEGIHUQOJBA-UHFFFAOYSA-N cyclohexane propionic acid Chemical compound OC(=O)CCC1CCCCC1 HJZLEGIHUQOJBA-UHFFFAOYSA-N 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000004037 social stress Effects 0.000 description 4
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 239000003176 neuroleptic agent Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QYIXCDOBOSTCEI-BPAAZKTESA-N (8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QYIXCDOBOSTCEI-BPAAZKTESA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101100379068 Caenorhabditis elegans apc-2 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000016952 Ear injury Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UAGJVSRUFNSIHR-UHFFFAOYSA-N Methyl levulinate Chemical compound COC(=O)CCC(C)=O UAGJVSRUFNSIHR-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 208000010399 Wasting Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- YYRDDAPQDPABPZ-UHFFFAOYSA-N methyl dec-5-enoate Chemical compound CCCCC=CCCCC(=O)OC YYRDDAPQDPABPZ-UHFFFAOYSA-N 0.000 description 2
- IZFGRAGOVZCUFB-UHFFFAOYSA-N methyl hexadec-9-enoate Chemical compound CCCCCCC=CCCCCCCCC(=O)OC IZFGRAGOVZCUFB-UHFFFAOYSA-N 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000011273 social behavior Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FWNZKPKGBYWNJO-KVVVOXFISA-N (z)-octadec-9-enoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FWNZKPKGBYWNJO-KVVVOXFISA-N 0.000 description 1
- BBNYCLAREVXOSG-UHFFFAOYSA-N 2-palmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CO)CO BBNYCLAREVXOSG-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- KRVXMNNRSSQZJP-PHFHYRSDSA-N 5alpha-androst-16-en-3alpha-ol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 KRVXMNNRSSQZJP-PHFHYRSDSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- 208000025940 Back injury Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- QYDYPVFESGNLHU-ZHACJKMWSA-N Methyl (9E)-9-octadecenoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC QYDYPVFESGNLHU-ZHACJKMWSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- KRVXMNNRSSQZJP-UHFFFAOYSA-N beta-androstenol Natural products C1C(O)CCC2(C)C3CCC(C)(C=CC4)C4C3CCC21 KRVXMNNRSSQZJP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002633 crown compound Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- ODPLFJYILBATKC-FOCLMDBBSA-N methyl (e)-hexadec-2-enoate Chemical compound CCCCCCCCCCCCC\C=C\C(=O)OC ODPLFJYILBATKC-FOCLMDBBSA-N 0.000 description 1
- PVVODBCDJBGMJL-CMDGGOBGSA-N methyl (e)-octadec-11-enoate Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)OC PVVODBCDJBGMJL-CMDGGOBGSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical class COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N methyl octadeca-9,12-dienoate Chemical compound CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
- 229960000769 periciazine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- MHRFLGDBPPPYBG-UHFFFAOYSA-N stigmasta-3,5,22-trien-7-one Natural products C1CC=CC2=CC(=O)C3C4CCC(C(C)C=CC(CC)C(C)C)C4(C)CCC3C21C MHRFLGDBPPPYBG-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Compounds Of Iron (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Inorganic Insulating Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP00980298A JP4750232B2 (ja) | 1998-01-21 | 1998-01-21 | ストレス、不安および攻撃性を低減するブタ鎮静フェロモン |
| US09/010,515 US6077867A (en) | 1998-01-21 | 1998-01-21 | Pig appeasing pheromones to decrease stress, anxiety and aggressiveness |
| EP98400117A EP0948963B1 (fr) | 1998-01-21 | 1998-01-21 | Compositions contenant des phéromones pour soulager le stress, l'anxiété et l'agressivité chez les cochons |
| CA2227706A CA2227706C (fr) | 1998-01-21 | 1998-01-21 | Pheromones d'apaisement pour diminuer le stress, l'anxiete et l'agressivite de porcs |
| NO980282A NO308197B1 (no) | 1998-01-21 | 1998-01-21 | Sammensetning og oppløsning derav for Õ minske stress, angst og agressivitet hos pattedyr inneholdende en blanding av fettsyrer eller derivater derav |
| PCT/EP1999/000375 WO1999037297A1 (fr) | 1998-01-21 | 1999-01-21 | Pheromones calmant les cochons, utilisees pour diminuer le stress, l'anxiete et l'agressivite |
| CZ20002700A CZ20002700A3 (cs) | 1998-01-21 | 1999-01-21 | Uklidňující feromonové prostředky pro snížení stresu, úzkosti a agresivity prasat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK10902000A3 SK10902000A3 (sk) | 2001-02-12 |
| SK285905B6 true SK285905B6 (sk) | 2007-10-04 |
Family
ID=31950877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1090-2000A SK285905B6 (sk) | 1998-01-21 | 1999-01-21 | Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6077867A (fr) |
| EP (2) | EP0948963B1 (fr) |
| JP (1) | JP4750232B2 (fr) |
| CN (1) | CN1217659C (fr) |
| AT (2) | ATE239464T1 (fr) |
| AU (1) | AU760614B2 (fr) |
| BR (1) | BRPI9907151C1 (fr) |
| CA (2) | CA2227706C (fr) |
| CZ (1) | CZ20002700A3 (fr) |
| DE (2) | DE69814343T2 (fr) |
| DK (2) | DK0948963T3 (fr) |
| ES (2) | ES2198661T3 (fr) |
| HU (1) | HU226882B1 (fr) |
| IL (1) | IL137257A0 (fr) |
| NO (2) | NO308197B1 (fr) |
| NZ (1) | NZ505813A (fr) |
| PL (1) | PL199144B1 (fr) |
| PT (2) | PT948963E (fr) |
| SK (1) | SK285905B6 (fr) |
| WO (1) | WO1999037297A1 (fr) |
| ZA (1) | ZA99426B (fr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| US20090253781A1 (en) * | 2002-05-24 | 2009-10-08 | Btg International Limited | Therapeutic compositions |
| US6054481A (en) * | 1998-01-21 | 2000-04-25 | Fideline | Pig appeasing pheromones for enhancing weight gain in a mammal |
| BR9917806B1 (pt) * | 1998-01-21 | 2013-06-18 | composiÇço de feromona para tratamento de estresse ou ansiedade em mamÍferos, e soluÇço. | |
| JP2003514855A (ja) * | 1999-10-13 | 2003-04-22 | チャコン，マルコ，エー． | カロリー制限の効果を模倣した治療的介入 |
| BR0112474A (pt) | 2000-07-14 | 2003-07-29 | Nestle Sa | Lipìdeos dietéticos para melhorar a pele e o pêlo de animais de estimação |
| FR2815227B1 (fr) * | 2000-10-17 | 2003-04-11 | Schwartz Laboratoires Robert | Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels |
| ES2186576B1 (es) * | 2001-10-11 | 2004-09-16 | Universitat De Les Illes Balears | Acido 2-hidroxioleico para utilizar como medicamento. |
| DE60332635D1 (de) | 2002-06-19 | 2010-07-01 | Fideline Le Rieu Neuf | Beruhigende vogel-pheromone zur verminderung von stress, angst und aggressivität |
| ES2345099T3 (es) * | 2002-06-19 | 2010-09-15 | Fideline | Feromonas tranquilizantes aviarias para disminuir el estres, la ansiedad y la agresividad. |
| KR100700884B1 (ko) | 2002-11-14 | 2007-03-29 | 백융기 | 약학적으로 유용한 노화 및 스트레스 조절용 신규 페로몬 화합물 및 그 분리정제방법 |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| EP2270034A3 (fr) | 2004-06-03 | 2011-06-01 | Athlomics Pty Ltd | Agents et procédé permettant le diagnostic de stress |
| EP1778213B1 (fr) * | 2004-07-16 | 2017-04-05 | BTG International Limited | Procédé pour la préparation de composés oligomères |
| EP1778615A4 (fr) * | 2004-07-20 | 2010-01-06 | Btg Int Ltd | Composes cetoniques oligomeres |
| EP1778212A4 (fr) * | 2004-07-23 | 2010-12-08 | Btg Int Ltd | Saccharides cetogenes |
| EP1793813A4 (fr) * | 2004-09-21 | 2011-05-18 | Btg Int Ltd | Traitement du trouble d'hyperactivite avec deficit de l'attention (thada) |
| US20070281892A1 (en) * | 2004-09-21 | 2007-12-06 | Martin Keith F | Dopaminergic Mimetics |
| US20090275670A1 (en) * | 2008-04-30 | 2009-11-05 | Marshall Gerald L | Dog pheromone formulation and delivery system |
| FR2931676B1 (fr) * | 2008-05-30 | 2011-01-14 | Ceva Sante Animale | Nouveaux modes d'administration d'un melange d'acides gras pour le traitement de mammiferes non humains |
| EP2346350A1 (fr) | 2008-09-18 | 2011-07-27 | Janssen Pharmaceutica, N.V. | Utilisation d'azapérone en vue de limiter le recours aux antibiotiques |
| US8741186B2 (en) | 2008-10-16 | 2014-06-03 | Ragasa Industrias, S.A. De C.V. | Vegetable oil of high dielectric purity, method for obtaining same and use in an electrical device |
| US9724483B2 (en) * | 2008-12-30 | 2017-08-08 | Gearbox, Llc | Method for administering an inhalable compound |
| US8871190B2 (en) | 2009-04-25 | 2014-10-28 | Sergeant's Pet Care Products, Inc. | Polymeric pheromone formulation and method of use to calm stress-related behavior in mammals over an extended period of time |
| CA2784626C (fr) * | 2009-12-21 | 2016-04-05 | Sergeant's Pet Care Product's Inc. | Compositions de pheromones et leurs procedes d'utilisation |
| CN102240279B (zh) * | 2011-05-13 | 2013-04-10 | 中国农业科学院北京畜牧兽医研究所 | 一种仔猪安抚剂及其制备方法和应用 |
| CN103126886A (zh) * | 2011-05-13 | 2013-06-05 | 中国农业科学院北京畜牧兽医研究所 | 一种仔猪安抚剂释放盒 |
| WO2013043879A1 (fr) * | 2011-09-20 | 2013-03-28 | Sergeants Pet Care Products, Inc. | Compositions d'interomone et leur utilisation pour modifier le comportement chez différentes espèces vertébrées |
| US9480688B2 (en) | 2011-09-20 | 2016-11-01 | Sergeant's Pet Care Products, Inc. | Pheromone compositions and their use to modify behavior in different vertebrate species |
| US9314018B2 (en) | 2012-06-25 | 2016-04-19 | Institut de Recherche en Semiochimie et Ethologie Appliquee | Feline scratch marking semiochemicals |
| HRP20220957T1 (hr) * | 2014-03-18 | 2022-10-28 | Institut de Recherche en Semiochimie et Ethologie Appliquée | Feromon za umirivanje mačaka |
| BR112016021468B1 (pt) * | 2014-03-18 | 2020-12-08 | Institut de Recherche en Semiochimie et Ethologie Appliquee | composições semioquímicas para reduzir conflitos sociais com gatos |
| EP2926809A1 (fr) * | 2014-03-31 | 2015-10-07 | Ceva Sante Animale | Compositions à base de phéromones destinées à traiter les problèmes comportementaux ou médicaux liés au stress des mammifères non humains |
| FR3031039B1 (fr) | 2014-12-24 | 2018-03-02 | Virbac | Composition apaisante pour animaux comprenant au moins un acide gras et de la nepetalactone |
| FR3031104B1 (fr) | 2014-12-26 | 2017-01-06 | Melchior Material & Life Science France | Composition pro-pheromonale apaisante pour les mammiferes |
| EP3247221A4 (fr) | 2015-01-23 | 2018-08-08 | Australasian Pork Research Institute Ltd | Produit et procédé procurant enrichissement et facilitant l'expression de comportements naturels chez les porcs |
| EP3259029B1 (fr) * | 2015-02-20 | 2020-10-21 | Société des Produits Nestlé S.A. | Acides gras à chaîne moyenne et leur triglycérides pour le traitement de l'anxiété |
| EP3124020A1 (fr) * | 2015-07-31 | 2017-02-01 | Ceva Sante Animale | Compositions de phéromones et utilisations de celles-ci |
| FR3046334B1 (fr) | 2015-12-31 | 2020-03-06 | Melchior Material And Life Science France | Composition solide pour le relargage controle de substances semiochimiques |
| EP3661600A4 (fr) | 2017-10-23 | 2021-08-11 | Epitracker, Inc. | Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique |
| KR101994338B1 (ko) * | 2017-10-25 | 2019-06-28 | 엘지이노텍 주식회사 | 사육장 관리 장치 및 방법 |
| US11529418B2 (en) | 2017-12-22 | 2022-12-20 | Ceva Sante Animale | Temperature-controlled semiochemical composition diffusers |
| JP2021525249A (ja) | 2018-05-23 | 2021-09-24 | エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． | 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法 |
| WO2021055926A1 (fr) * | 2019-09-19 | 2021-03-25 | Texas Tech University System | Phéromone néonatale maternelle porcine |
| AU2021224961A1 (en) | 2020-02-19 | 2022-09-08 | Marel Meat A/S | Method and system for pre-stunning and/or stunning animals |
| EP4199751A4 (fr) * | 2020-08-20 | 2024-09-04 | Epitracker Inc | Compositions et méthodes d'amélioration de l'humeur |
| CN112370528B (zh) * | 2020-10-23 | 2022-04-08 | 宁波三生生物科技股份有限公司 | 一种具标识功能的信息素组合物及其制剂 |
| CN114452238B (zh) * | 2022-01-07 | 2023-10-27 | 佛山市南海东方澳龙制药有限公司 | 具有安抚作用的宠物药浴香波及其制备方法 |
| WO2023177427A1 (fr) * | 2022-03-14 | 2023-09-21 | Fera Diagnostics And Biologicals Corp. | Compositions d'acides gras |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61249371A (ja) * | 1985-04-30 | 1986-11-06 | Nippon Oil & Fats Co Ltd | 栄養飲料組成物 |
| JP3039817B2 (ja) * | 1990-09-28 | 2000-05-08 | 株式会社資生堂 | シャンプー組成物 |
| ES2034888B1 (es) * | 1991-07-11 | 1994-02-16 | Madaus Cerafarm Lab | Procedimiento de obtencion de la fraccion acida total de los extractos lipidicos de los frutos del sabal serrulata. |
| US5425963A (en) * | 1991-09-17 | 1995-06-20 | Church & Dwight Co., Inc. | High purity fatty acid salt products |
| WO1993011987A1 (fr) * | 1991-12-13 | 1993-06-24 | Viktor Nikolaevich Kizilov | Vehicule sur coussin d'air |
| SE9200541D0 (sv) * | 1992-02-24 | 1992-02-24 | Kabi Pharmacia Ab | New usee of omega-3-fatty acids |
| WO1993018667A1 (fr) * | 1992-03-20 | 1993-09-30 | Church & Dwight Company, Inc. | Produits d'alimentation enrobes a base de sel d'un acide gras |
| CA2151820C (fr) * | 1993-01-15 | 2000-11-28 | Stephen Joseph Demichele | Lipides structures |
| DE69512509T2 (de) * | 1995-02-03 | 2000-05-31 | Fideline, Le Rieu Neuf | Eigenschaften von Gesichtpheromonen von Katzen |
| DE19511572C2 (de) * | 1995-03-29 | 1998-02-26 | Henkel Kgaa | Niedrigviskose Trübungsmittelkonzentrate |
| DE19615777C2 (de) * | 1996-04-20 | 1999-04-01 | Henkel Kgaa | Verwendung von Milchsäure-Milchsäureester-Mischungen |
| BR9917806B1 (pt) * | 1998-01-21 | 2013-06-18 | composiÇço de feromona para tratamento de estresse ou ansiedade em mamÍferos, e soluÇço. |
-
1998
- 1998-01-21 EP EP98400117A patent/EP0948963B1/fr not_active Expired - Lifetime
- 1998-01-21 JP JP00980298A patent/JP4750232B2/ja not_active Expired - Lifetime
- 1998-01-21 ES ES98400117T patent/ES2198661T3/es not_active Expired - Lifetime
- 1998-01-21 NO NO980282A patent/NO308197B1/no not_active IP Right Cessation
- 1998-01-21 DK DK98400117T patent/DK0948963T3/da active
- 1998-01-21 CA CA2227706A patent/CA2227706C/fr not_active Expired - Lifetime
- 1998-01-21 DE DE69814343T patent/DE69814343T2/de not_active Expired - Lifetime
- 1998-01-21 AT AT98400117T patent/ATE239464T1/de active
- 1998-01-21 US US09/010,515 patent/US6077867A/en not_active Expired - Lifetime
- 1998-01-21 PT PT98400117T patent/PT948963E/pt unknown
-
1999
- 1999-01-21 ES ES99903663T patent/ES2234236T3/es not_active Expired - Lifetime
- 1999-01-21 ZA ZA9900426A patent/ZA99426B/xx unknown
- 1999-01-21 CZ CZ20002700A patent/CZ20002700A3/cs unknown
- 1999-01-21 BR BRPI9907151A patent/BRPI9907151C1/pt not_active IP Right Cessation
- 1999-01-21 WO PCT/EP1999/000375 patent/WO1999037297A1/fr active IP Right Grant
- 1999-01-21 CN CN998032190A patent/CN1217659C/zh not_active Expired - Lifetime
- 1999-01-21 DE DE69922633T patent/DE69922633T2/de not_active Expired - Lifetime
- 1999-01-21 PL PL341867A patent/PL199144B1/pl unknown
- 1999-01-21 AT AT99903663T patent/ATE284688T1/de active
- 1999-01-21 AU AU24237/99A patent/AU760614B2/en not_active Expired
- 1999-01-21 EP EP99903663A patent/EP1047415B1/fr not_active Expired - Lifetime
- 1999-01-21 SK SK1090-2000A patent/SK285905B6/sk not_active IP Right Cessation
- 1999-01-21 NZ NZ505813A patent/NZ505813A/en not_active IP Right Cessation
- 1999-01-21 HU HU0101312A patent/HU226882B1/hu unknown
- 1999-01-21 DK DK99903663T patent/DK1047415T3/da active
- 1999-01-21 CA CA2318392A patent/CA2318392C/fr not_active Expired - Lifetime
- 1999-01-21 IL IL13725799A patent/IL137257A0/xx active IP Right Grant
- 1999-01-21 PT PT99903663T patent/PT1047415E/pt unknown
-
2000
- 2000-07-19 NO NO20003693A patent/NO329205B1/no not_active IP Right Cessation
- 2000-07-21 US US09/621,554 patent/US6384252B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK285905B6 (sk) | Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie | |
| Miranda-de la Lama et al. | The importance of social behaviour for goat welfare in livestock farming | |
| Christensen et al. | Effects of repeated regrouping on horse behaviour and injuries | |
| Pulliam et al. | Safety of ivermectin in target animals | |
| US6169113B1 (en) | Pig appeasing pheromones to decrease stress, anxiety and aggressiveness | |
| Simitzis et al. | Effect of breed and age on sexual behaviour of rams | |
| JP4754688B2 (ja) | ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン | |
| Roelofs et al. | The effect of fenceline bull exposure on expression of oestrus in dairy cows | |
| Rowell et al. | The effects of short-term medroxyprogesterone acetate on rut related behaviors, semen characteristics and fertility in farmed reindeer bulls | |
| WO2023177427A1 (fr) | Compositions d'acides gras | |
| CN118843460A (zh) | 脂肪酸组合物 | |
| Aviles-Rosa | The effect of Swine's semiochemicals on pigs' behavior, physiology and production | |
| Mimiko | Relationships between behavioral measures and productivity in finishing beef cattle | |
| Shrestha et al. | An evaluation of boar pheromone spray to aid the stimulation and detection of estrus in small farms in Nepal | |
| Munari | EVALUATION OF RABBIT PRODUCTION AND WELFARE | |
| Mondal et al. | Sexual behaviour response of Sahiwal breeding bulls exposed to different estrus specific molecules | |
| MXPA00007189A (en) | Pig appeasing pheromones to decrease stress, anxiety and aggressiveness | |
| KR20110084162A (ko) | 성장성 향상을 위한 아자페론의 용도 | |
| Dahlgren | A comparison of group housing and individual housing for dairy bulls kept for breeding | |
| Hicks | Acute stress effects on pig performance, immunity, and behavior | |
| Mbaya et al. | Mixed Infection of Notodres cati and Ancylostoma caninum Among Captive Lions (Panthera leo) at the Sanda Kyarimi Park, Maiduguri, Nigeria | |
| Erp-van der Kooij | Coping behaviour in pigs: consequences for welfare and performance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Expiry date: 20190121 |